Advertisement

Topics

STADA Arzneimittel AG Company Profile

20:27 EDT 22nd June 2018 | BioPortfolio

STADA - Generics with “value for money”
Generics contributed 73.2% to sales in 2006 (previous year: 74.3%) and represents STADA’s largest core segment by far. In 2006, sales in the generics core segment rose by 20% to EUR 911.2 million (2005: EUR 759.3 million1)). A part of this growth is based on the acquisition of the Serbian Hemofarm, whose product portfolio includes approx. 75% of generics. Group sales in the generics core segment rose by 32% to EUR 821.5 million in the first nine months of 2007 (1-9/2006: EUR 624.7 million2)).

Generics are drugs which, after expiration of the patent or other relevant commercial property rights, are offered in the same quality but for lower prices than products of an initial supplier having the same active ingredient. This means generics are typical “multisource products” with active ingredients that any supplier can readily procure.

Generics have a high structural growth potential. The basis for this on the one hand is the pressure to contain costs in numerous national health care markets because generics allow, in many indication areas, a low-cost medical therapy without quality cutbacks. On the other hand, the continuous expiration of patents or other commercial property rights ensures a constant automatic expansion of market potential available for generic competition. Historical data as well as forecast market data demonstrate the growth momentum of generics which is characterized by these two sustainable market trends.

There is no question that spending restraints in the different national health care systems form the basis for the long-term growth potential of generics suppliers. However, due to the associated low price expectations, the generics market is a very price-sensitive segment. Reactions to lasting or temporary challenges occurring in individual national markets due to regulation and /or competition must be specifically and flexibly targeted at the individual national market.

In Germany, the Group's generic drugs are marketed by the Group subsidiary STADApharm GmbH, STADA Medical GmbH, ALIUD Pharma GmbH & Co. KG, cell pharm GmbH and Hemofarm GmbH3).

STADA´s sales network outside of Germany consists the following sales companies in Europe: Austria, Belgium, Bosnia, the Czech Republic, Denmark, Finland, France, Ireland, Italy, Lithuania, Macedonia, Montenegro, the Netherlands, Portugal, Romania, Russia, Serbia, Spain, Sweden, Ukraine and United Kingdom.

Further own sales companies outside of Europe are in: China, Kazakhstan, Vietnam, Philippines and Thailand.

Location

5 Cedar Brook Drive
Bad Vilbel
D-61118
Germany

Contact

Phone: +49 6101 603-0
Fax: +49 6101 603-259
Email: info@stada.de


News Articles [118 Associated News Articles listed on BioPortfolio]

DGAP-Adhoc: STADA Arzneimittel AG: Vorstand der STADA Arzneimittel AG beschließt Antragstellung betreffend Wechsel des Börsensegments (deutsch)

STADA Arzneimittel AG: Vorstand der STADA Arzneimittel AG beschließt Antragstellung betreffend Wechsel des Börsensegments DGAP-Ad-hoc: STADA Arzneimittel AG / Schlagwort(e): Sonstiges STADA Arznei.....

DGAP-News: STADA Arzneimittel AG: Personelle Weichenstellungen im Management von STADA (deutsch)

STADA Arzneimittel AG: Personelle Weichenstellungen im Management von STADA DGAP-News: STADA Arzneimittel AG / Schlagwort(e): Sonstiges/Sonstiges STADA Arzneimittel AG: Personelle Weichenstellunge...

DGAP-News: STADA Arzneimittel AG: Aufforderung zu Anpassungen der

STADA Arzneimittel AG: Aufforderung zu Anpassungen der STADA-Anleihe 2015/2022 DGAP-News: STADA Arzneimittel AG / Schlagwort(e): Anleihe STADA Arzneimittel AG: Aufforderung zu Anpassungen der STAD...

DGAP-News: STADA Arzneimittel AG: EMA startet Bewertung des erneuten Zulassungsantrags für Pegfilgrastim-Biosimilar (deutsch)

STADA Arzneimittel AG: EMA startet Bewertung des erneuten Zulassungsantrags für Pegfilgrastim-Biosimilar DGAP-News: STADA Arzneimittel AG / Schlagwort(e): Sonstiges STADA Arzneimittel AG: EMA star...

DGAP-News: STADA Arzneimittel AG: Hauptversammlung stimmt Tagesordnungspunkten mit großer Mehrheit zu (deutsch)

STADA Arzneimittel AG: Hauptversammlung stimmt Tagesordnungspunkten mit großer Mehrheit zu DGAP-News: STADA Arzneimittel AG / Schlagwort(e): Hauptversammlung STADA Arzneimittel AG: Hauptversammlun...

STADA Arzneimittel AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements

STADA Arzneimittel AG / Preliminary announcement on the disclosure of financial statements 26.02.2018 / 14:16 Preliminary announcement of the publication of quarterly reports and quarterly/interim st...

STADA Arzneimittel Aktie: Euphorie sieht anders aus!

Die Aktie von Stada Arzneimittel kommt aktuell nicht recht vom Fleck. Nach einem großen Sprung im vergangenen Dezember bewegt das Papier sich hauptsächlich seitwärts mit einer leicht negativen Tend...

STADA Arzneimittel AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

STADA Arzneimittel AG / Preliminary announcement on the disclosure of financial statements 26.02.2018 / 14:06 Preliminary announcement of the publication of financial reports according to Articles 11...

Drugs and Medications [5 Associated Drugs and Medications listed on BioPortfolio]

Bekunis natures gentle stimulant laxative [roha arzneimittel GmbH]

Bekunis Nature's Gentle Stimulant Laxative Tablets

Bekunis natures gentle laxative herbal tea [roha arzneimittel GmbH]

Bekunis Nature's Gentle Laxative Herbal Tea

Bekunis natures gentle laxative instant tea [roha arzneimittel GmbH]

Bekunis Nature's Gentle Laxative Instant Tea

Ampicillin [DAVA Pharmaceuticals, Inc.]

AMPICILLIN CAPSULES, USP 250 mg and 500 mgAMPICILLIN FOR ORAL SUSPENSION, USP 125 mg/5 mL and 250 mg/5 mLRx Only

Penicillin v potassium [Rebel Distributors Corp]

Penicillin-VKPenicillin V Potassium Tablets, USP500 mg (800,000 Units)

PubMed Articles [0 Results]

None

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction

An open label, randomized controlled study in a Norwegian population with meibomian gland dysfunction. Patients will be randomized to one of two groups: THERA°PEARL Eye Mask (Bausch & Lom...

Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride

to evaluate the bioavailability of ambroxol hydrochloride soft pastilles (test formulation), manufactured by Bolder Arzneimittel GmbH & Co. KG to Boehringer Ingelheim compared to ambroxol ...

Companies [7 Associated Companies listed on BioPortfolio]

STADA Arzneimittel AG

STADA - Generics with “value for money” Generics contributed 73.2% to sales in 2006 (previous year: 74.3%) and represents STADA’s largest core segment by far. In 2006, sales in the generics cor...

Bundesinstitut für Arzneimittel und Medizinprodukte

Das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) ist eine selbständige Bundesoberbehörde im Geschäftsbereich des Bundesministeriums für Gesundheit. Aufgrund des Gesetzes über die ...

Laves-Arzneimittel GmbH

Nil

RIEMSER Arzneimittel AG

RIEMSER Arzneimittel AG is a medium-sized pharmaceutical company engaging in research and headquartered in the West Pomeranian town of Greifswald - Island of Riems. The stockholding company (AG) opera...

HERMES PHARMA

HERMES PHARMA specializes in developing and manufacturing user-friendly solid oral dosage forms – including effervescent and chewable tablets, instant drinks and orally disintegrating granules...

More Information about "STADA Arzneimittel AG" on BioPortfolio

We have published hundreds of STADA Arzneimittel AG news stories on BioPortfolio along with dozens of STADA Arzneimittel AG Clinical Trials and PubMed Articles about STADA Arzneimittel AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of STADA Arzneimittel AG Companies in our database. You can also find out about relevant STADA Arzneimittel AG Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...


Corporate Database Quicklinks



Searches Linking to this Company Record